Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Drug Research
Drug Discovery & Development
Return to: PBR Home | Drug Research | Drug Discovery & Development | News
Search Refinements

Drug Discovery & Development News

View news from other Pharmaceutical sectors:
31-45 of 4385 results
Prexton Therapeutics raises €29m in Series B Financing
Prexton Therapeutics has closed a €29m Series B round led by Forbion Capital Partners and Seroba Life Sciences.
Drug Research > Drug Discovery & Development > News
Acticor Biotech raises €1.5m in new funding
Acticor Biotech, a bio-pharmaceutical company focused on the treatment of acute ischemic stroke, has raised €1,5m from CapDecisif Management.
Drug Research > Drug Discovery & Development > News
Chondrial Therapeutics secures $22.6m in Series A financing
Biotechnology company Chondrial Therapeutics, focused on the treatment of rare mitochondrial diseases, has secured up to $22.6m in Series A financing led by Deerfield Management besides naming a new president and CEO in Carole Ben-Maimon, MD.
Drug Research > Drug Discovery & Development > News
Portola Pharma assigns AndexXa royalties to HealthCare Royalty Partners
Portola Pharmaceuticals has sold the royalty rights to AndexXa (andexanet alfa) to HealthCare Royalty Partners (HCR) for up to $150m.
Drug Research > Drug Discovery & Development > News
Tarveda Therapeutics completes $30m Series D equity financing
Tarveda Therapeutics has raised $30m in series D financing to advance pentarin miniaturized drug conjugates.
Drug Research > Drug Discovery & Development > News
Ferring, Enteris to develop oral formulation of peptide-based injectable therapeutic
Ferring Pharmaceuticals and Enteris BioPharma have signed a license agreement to develop an oral formulation of a peptide-based injectable therapeutic.
Drug Research > Drug Discovery & Development > News
Biscayne Neurotherapeutics raises $3m for antiepileptic compound
Biscayne Pharmaceuticals has raised financing for its new spin-out, Biscayne Neurotherapeutics, which was recently established to develop its biopharmaceutical assets for the treatment of neurological disorders.
Drug Research > Drug Discovery & Development > News
Celgene to buy biotechnology company Delinia
Celgene has agreed to acquire Delinia, a biotechnology company developing novel therapeutics for the treatment of autoimmune diseases.
Drug Research > Drug Discovery & Development > News
Johnson & Johnson to buy Actelion for $30bn
By PBR Staff Writer
US healthcare giant Johnson & Johnson (J&J) has agreed to acquire Swiss biopharmaceutical firm Actelion for $30bn.
Drug Research > Drug Discovery & Development > News
Connect secures $25m financing to advance immune modulators clinical development
Connect Biopharmaceuticals has completed a $20m Series A financing to advance clinical development of novel immune modulators.
Drug Research > Drug Discovery & Development > News
Discuva secures Innovate UK grant for new antibiotics development
Innovate UK has awarded a £1.5m Biomedical Catalyst early-stage award to drug discovery firm Discuva for the development of novel antibiotics to tackle the issue of multidrug-resistance and life-threatening bacterial infections.
Drug Research > Drug Discovery & Development > News
Cue Biopharma raises $26M in funding
Cue Biopharma has announced a total of $26m of invested private capital, led by MDB Capital Group, to develop next-generation biologics to selectively control T Cell activity.
Drug Research > Drug Discovery & Development > News
ELC Group partners with PSR Group for advanced drug development
Global life sciences partner ELC Group is collaborating with New Zealand-based research and development firm Pharma Scientific Research (PSR Group) to create highly advanced products for the pharmaceutical market.
Drug Research > Drug Discovery & Development > News
Merck, Domain Therapeutics partner to co-develop adenosine receptor antagonists
Merck has entered into a collaboration and licensing agreement with French based Domain Therapeutics to explore the potential of adenosine inhibition in the development of novel immuno-oncology agents.
Drug Research > Drug Discovery & Development > News
Cytori to buy Azaya’s nanoparticle Development Platform
By PBR Staff Writer
Cytori Therapeutics has agreed to acquire certain assets from oncology firm Azaya Therapeutics in a deal potentially worth $170m.
Drug Research > Drug Discovery & Development > News
31-45 of 4385 results